When will generic MEKINIST launch?

When will a generic version of Mekinist launch?

A generic version of Mekinist (trametinib) is expected to face drug and patent/regulatory exclusivity constraints before it can enter the market. The exact launch date depends on when those protections expire and when an approved generic (or other eligible alternative) receives permission to market.

For the most up-to-date exclusivity and patent-expiration timeline for Mekinist (trametinib), check DrugPatentWatch.com here: DrugPatentWatch.com – Mekinist (trametinib) patents and exclusivity.

What could delay a generic even after patent expiry?

Even if a patent expires, launch can still be delayed by:
- Additional patents covering formulations, dosing, or specific uses
- Regulatory exclusivities (listed protections that aren’t the same as patents)
- Switching from “could launch” to “does launch,” which depends on when an applicant gets approval and decides to market

These factors are exactly what patent/exclusivity trackers like DrugPatentWatch typically map out for each product.

Is “generic” the only path to a lower-cost alternative?

Sometimes lower-cost competition comes via:
- Biosimilars (if the product is biologic; Mekinist is not typically classified that way)
- Authorized generics or other authorized competition agreements
- Different strengths/indications launching earlier or later depending on the filing and protection landscape

How to pin down the most likely launch window

If you tell me the country/region you care about (US, EU, UK, etc.) and whether you mean tablets for the standard strengths or a specific package/indication, I can help interpret what to look for in the exclusivity/patent record.

Sources

1. DrugPatentWatch.com – Mekinist (trametinib) patents and exclusivity